00:05 , Nov 6, 2018 |  BC Extra  |  Company News

Management tracks: Audentes, Veloxis

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) appointed CEO and co-founder Matthew Patterson as chairman. Patterson has been a board member since 2012. Audentes also appointed board member Louis Lange as lead independent director. Lange...
00:58 , Dec 15, 2017 |  BioCentury  |  Finance

Fewer, further

AmorChem hopes to garner higher returns with its second early stage life sciences fund by financing fewer projects further into development. The Montreal VC raised C$44.2 million (US$34.4 million) toward a planned C$50 million (US$38.9...
04:21 , Dec 8, 2017 |  BC Week In Review  |  Financial News

AmorChem raises C$44.2M toward second fund

Montreal-based VC AmorChem raised C$44.2 million ($34.8 million) toward a planned C$50 million ($39.4 million) life sciences fund. AmorChem II Fund will invest in seed rounds for biotechs emerging from universities and research centers in...
23:45 , Dec 6, 2017 |  BC Extra  |  Financial News

AmorChem raises C$44.2M towards second fund

Montreal VC AmorChem raised C$44.2 million ($34.8 million) towards a planned C$50 million ($39.4 million) life sciences fund. AmorChem II Fund will invest in seed rounds for biotechs emerging from universities and research centers in...
17:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

SpecificiT completes seed financing

On Sept. 11, cancer company SpecificiT Pharma Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures . Accel-Rx Health Sciences Accelerator and founding investor AmorChem also participated....
20:59 , Jun 1, 2017 |  BC Week In Review  |  Company News

Corbin partners with Proteorex and U of Dundee to identify USP15 inhibitors

Corbin Therapeutics Inc. (Montreal, Canada) partnered with Proteorex Therapeutics Inc. (Toronto, Canada) and the University of Dundee (Dundee, U.K.) in separate deals to discover inhibitors of ubiquitin specific peptidase 15 (USP15) . Corbin said USP15...
20:05 , Jan 12, 2017 |  BC Innovations  |  Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti- VEGF therapies. Semaphorins are...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Universite Laval, AmorChem deal

The university granted VC fund AmorChem an exclusive, worldwide license to a gene therapy program to treat Friedreich’s Ataxia. The university plans to optimize the gene therapy and test it in a mouse model of...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

University of Montreal, AmorChem deal

The University of Montreal granted VC fund AmorChem exclusive, worldwide rights to a program targeting CD36 (GPIV) to treat atherosclerosis. AmorChem, which invested an undisclosed amount in the program, said it plans to validate lead...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Mining Quebec

An option deal with Roche (SIX:ROG; OTCQX:RHHBY) marks the first potential exit for early stage life science venture fund AmorChem and its in-house medicinal chemistry CRO, NuChem Therapeutics Inc. The deal gives Roche an option...